Yanyang Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yanyang Hu has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Colin Carlock
Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana
29 shared publications - Diego Ruiz-Avila
Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana
29 shared publications - Frederick Nguele Meke
Borch Department of Medicinal Chemistry and Molecular Pharmacology
29 shared publications - Jinan Ayub
Indiana University School of Medicine
29 shared publications - Jinmin Miao
Borch Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University
29 shared publications - Qinglin Li
Borch Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, 720 Clinic Drive, West Lafayette, IN 47907, U.S.A
29 shared publications
Latest Publications
- Open Access
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Figure S4 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models
Prl2 deletion upregulates PTEN to inhibit Akt signaling and hinder tumor cell proliferation in Tp53 heterozygous mice
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models
Prl2 deletion upregulates PTEN to inhibit Akt signaling and hinder tumor cell proliferation in Tp53 heterozygous mice
- Open Access
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 3 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models
Prl2 deletion enhances survival and hinders tumor growth rate in tamoxifen-inducible Tp53−/− mouse but does not affect tumor initiation. A, PCR genotyping to identify different genotypes in the study. B, Kaplan–Meier survival plot for thymic lymphoma-free survival in tamoxifen-inducible Tp53−/− n = 43 and inducible Tp53−/−; Prl2−/− n = 33. C, Bar graph representing percent tumor incidence in inducible Tp53−/− background with or without inducible Prl2 deletion. Dot plots representing: The mass of thymus/thymic lymphoma over time in inducible Tp53−/− n = 9–20 per timepoint and inducible Tp53−/−; Prl2−/− n = 8–14 per timepoint (D). E, Thymocyte population ratios 9 weeks after inducing Tp53 deletion with or without Prl2 deletion. F, Thymocyte population ratios 12 weeks after inducing Tp53 deletion with or without Prl2 deletion. DP: Double positive (CD4+ CD8+). DN: Double negative (CD4− CD8−). log-rank test performed for Kaplan–Meier survival curves and Student t test performed for all other analysis. Data are shown as mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 3 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models
Prl2 deletion enhances survival and hinders tumor growth rate in tamoxifen-inducible Tp53−/− mouse but does not affect tumor initiation. A, PCR genotyping to identify different genotypes in the study. B, Kaplan–Meier survival plot for thymic lymphoma-free survival in tamoxifen-inducible Tp53−/− n = 43 and inducible Tp53−/−; Prl2−/− n = 33. C, Bar graph representing percent tumor incidence in inducible Tp53−/− background with or without inducible Prl2 deletion. Dot plots representing: The mass of thymus/thymic lymphoma over time in inducible Tp53−/− n = 9–20 per timepoint and inducible Tp53−/−; Prl2−/− n = 8–14 per timepoint (D). E, Thymocyte population ratios 9 weeks after inducing Tp53 deletion with or without Prl2 deletion. F, Thymocyte population ratios 12 weeks after inducing Tp53 deletion with or without Prl2 deletion. DP: Double positive (CD4+ CD8+). DN: Double negative (CD4− CD8−). log-rank test performed for Kaplan–Meier survival curves and Student t test performed for all other analysis. Data are shown as mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
- Open Access
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 5 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models
Prl2 deletion upregulates PTEN to inhibit Akt signaling and hinder tumor cell proliferation in inducible Tp53−/− mice. A, Representative Western blot analysis from inducible Tp53−/− and inducible Tp53−/−; Prl2−/−–derived thymic lymphomas to determine expression of PTEN, PUMA, BAX, p21, cyclin D1, p27, as well as the expression and activation of Akt and Akt targets. The actin loading control shown is the same as that in Fig. 4A. B, Dot plot for quantification of PTEN and Akt activation. C, Dot plot for quantification of Western blot analysis for the activation of Akt targets mTOR and GSK3β. D, Dot plot for quantification of the expression of Tp53 targets PUMA, BAX, p21, and cyclin D1. E, Dot plot for quantification of FoxOs activation and p27 expression. Data shown as mean ± SEM for samples obtained 12 weeks after tamoxifen treatment, Tp53−/− n = 10–20, Tp53−/−; Prl2−/− n = 10–14; *, P < 0.05; ***, P < 0.001; ****, P < 0.0001.
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 5 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models
Prl2 deletion upregulates PTEN to inhibit Akt signaling and hinder tumor cell proliferation in inducible Tp53−/− mice. A, Representative Western blot analysis from inducible Tp53−/− and inducible Tp53−/−; Prl2−/−–derived thymic lymphomas to determine expression of PTEN, PUMA, BAX, p21, cyclin D1, p27, as well as the expression and activation of Akt and Akt targets. The actin loading control shown is the same as that in Fig. 4A. B, Dot plot for quantification of PTEN and Akt activation. C, Dot plot for quantification of Western blot analysis for the activation of Akt targets mTOR and GSK3β. D, Dot plot for quantification of the expression of Tp53 targets PUMA, BAX, p21, and cyclin D1. E, Dot plot for quantification of FoxOs activation and p27 expression. Data shown as mean ± SEM for samples obtained 12 weeks after tamoxifen treatment, Tp53−/− n = 10–20, Tp53−/−; Prl2−/− n = 10–14; *, P < 0.05; ***, P < 0.001; ****, P < 0.0001.
- Open Access
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Figure S3 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models
Prl2 deletion inhibits tumor cell proliferations
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models
Prl2 deletion inhibits tumor cell proliferations
- Open Access
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 5 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models
Prl2 deletion upregulates PTEN to inhibit Akt signaling and hinder tumor cell proliferation in inducible Tp53−/− mice. A, Representative Western blot analysis from inducible Tp53−/− and inducible Tp53−/−; Prl2−/−–derived thymic lymphomas to determine expression of PTEN, PUMA, BAX, p21, cyclin D1, p27, as well as the expression and activation of Akt and Akt targets. The actin loading control shown is the same as that in Fig. 4A. B, Dot plot for quantification of PTEN and Akt activation. C, Dot plot for quantification of Western blot analysis for the activation of Akt targets mTOR and GSK3β. D, Dot plot for quantification of the expression of Tp53 targets PUMA, BAX, p21, and cyclin D1. E, Dot plot for quantification of FoxOs activation and p27 expression. Data shown as mean ± SEM for samples obtained 12 weeks after tamoxifen treatment, Tp53−/− n = 10–20, Tp53−/−; Prl2−/− n = 10–14; *, P < 0.05; ***, P < 0.001; ****, P < 0.0001.
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 5 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models
Prl2 deletion upregulates PTEN to inhibit Akt signaling and hinder tumor cell proliferation in inducible Tp53−/− mice. A, Representative Western blot analysis from inducible Tp53−/− and inducible Tp53−/−; Prl2−/−–derived thymic lymphomas to determine expression of PTEN, PUMA, BAX, p21, cyclin D1, p27, as well as the expression and activation of Akt and Akt targets. The actin loading control shown is the same as that in Fig. 4A. B, Dot plot for quantification of PTEN and Akt activation. C, Dot plot for quantification of Western blot analysis for the activation of Akt targets mTOR and GSK3β. D, Dot plot for quantification of the expression of Tp53 targets PUMA, BAX, p21, and cyclin D1. E, Dot plot for quantification of FoxOs activation and p27 expression. Data shown as mean ± SEM for samples obtained 12 weeks after tamoxifen treatment, Tp53−/− n = 10–20, Tp53−/−; Prl2−/− n = 10–14; *, P < 0.05; ***, P < 0.001; ****, P < 0.0001.
- Open Access
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Figure S2 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models
Experiemental design for tamoxifen inducible Tp53 deletion w/o Prl2 deletion
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models
Experiemental design for tamoxifen inducible Tp53 deletion w/o Prl2 deletion
- Open Access
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 3 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models
Prl2 deletion enhances survival and hinders tumor growth rate in tamoxifen-inducible Tp53−/− mouse but does not affect tumor initiation. A, PCR genotyping to identify different genotypes in the study. B, Kaplan–Meier survival plot for thymic lymphoma-free survival in tamoxifen-inducible Tp53−/− n = 43 and inducible Tp53−/−; Prl2−/− n = 33. C, Bar graph representing percent tumor incidence in inducible Tp53−/− background with or without inducible Prl2 deletion. Dot plots representing: The mass of thymus/thymic lymphoma over time in inducible Tp53−/− n = 9–20 per timepoint and inducible Tp53−/−; Prl2−/− n = 8–14 per timepoint (D). E, Thymocyte population ratios 9 weeks after inducing Tp53 deletion with or without Prl2 deletion. F, Thymocyte population ratios 12 weeks after inducing Tp53 deletion with or without Prl2 deletion. DP: Double positive (CD4+ CD8+). DN: Double negative (CD4− CD8−). log-rank test performed for Kaplan–Meier survival curves and Student t test performed for all other analysis. Data are shown as mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 3 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models
Prl2 deletion enhances survival and hinders tumor growth rate in tamoxifen-inducible Tp53−/− mouse but does not affect tumor initiation. A, PCR genotyping to identify different genotypes in the study. B, Kaplan–Meier survival plot for thymic lymphoma-free survival in tamoxifen-inducible Tp53−/− n = 43 and inducible Tp53−/−; Prl2−/− n = 33. C, Bar graph representing percent tumor incidence in inducible Tp53−/− background with or without inducible Prl2 deletion. Dot plots representing: The mass of thymus/thymic lymphoma over time in inducible Tp53−/− n = 9–20 per timepoint and inducible Tp53−/−; Prl2−/− n = 8–14 per timepoint (D). E, Thymocyte population ratios 9 weeks after inducing Tp53 deletion with or without Prl2 deletion. F, Thymocyte population ratios 12 weeks after inducing Tp53 deletion with or without Prl2 deletion. DP: Double positive (CD4+ CD8+). DN: Double negative (CD4− CD8−). log-rank test performed for Kaplan–Meier survival curves and Student t test performed for all other analysis. Data are shown as mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
- Open Access
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Figure S5 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models
Prl2 deletion does not affect Erk activation in inducible Tp53-/- mice derived thymic lymphomas
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models
Prl2 deletion does not affect Erk activation in inducible Tp53-/- mice derived thymic lymphomas
- Open Access
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Figure S3 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models
Prl2 deletion inhibits tumor cell proliferations
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models
Prl2 deletion inhibits tumor cell proliferations
- Open Access
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 2 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models
Prl2 deletion enhances survival in constitutive Tp53 deficiency mouse models. A, Mating strategy for the generation of constitutive Tp53-deficient mice with or without constitutive Prl2 deletion. B, PCR genotyping to identify different genotypes in the study. Kaplan–Meier survival plot for overall survival in constitutive Tp53-H (C) and Tp53-KO (D) backgrounds with or without constitutive Prl2 deletion. E, Bar graphs representing percent tumor incidence in Tp53-H background with or without Prl2 deletion. P values are indicated in figures and a P value <0.05 is considered statistically significant. WT n = 44, Prl2-KO n = 31, Tp53-H n = 118, Tp53-H; Prl2-KO n = 108.
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 2 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models
Prl2 deletion enhances survival in constitutive Tp53 deficiency mouse models. A, Mating strategy for the generation of constitutive Tp53-deficient mice with or without constitutive Prl2 deletion. B, PCR genotyping to identify different genotypes in the study. Kaplan–Meier survival plot for overall survival in constitutive Tp53-H (C) and Tp53-KO (D) backgrounds with or without constitutive Prl2 deletion. E, Bar graphs representing percent tumor incidence in Tp53-H background with or without Prl2 deletion. P values are indicated in figures and a P value <0.05 is considered statistically significant. WT n = 44, Prl2-KO n = 31, Tp53-H n = 118, Tp53-H; Prl2-KO n = 108.